Liraglutide, commercialized under the brand name Saxenda, is a daily injectable treatment
Symptoms include upper right abdominal pain, nausea, and vomiting
More serious risks include pancreatitis, gallbladder disease, acute kidney injury (particularly with dehydration), hypoglycemia (when combined with insulin or sulfonylureas), and thyroid C-cell tumors in animal studies
Study characteristics All but one [25] of the RCTs included in this meta-analysis were phase 3 trials
Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance
These drugs include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is actually a dual GIP/GLP-1 receptor agonist